Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • ACA Enrollment
  • Ebola
  • PFAS in Drinking Water
  • Drug-Related Driving Deaths
  • Black Maternal Health

WHAT'S NEW

  • ACA Enrollment
  • Ebola
  • PFAS in Drinking Water
  • Drug-Related Driving Deaths
  • Black Maternal Health

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Sep 26 2024

Full Issue

FDA To Consider Approving First New Schizophrenia Drug In Over 30 Years

During clinical trials, Bristol Myers Squibb's KarXT was said to offer better treatment with fewer side effects. Meanwhile, Pfizer's sickle cell disease treatment Oxbryta was withdrawn from all markets over concerns about the risk of a painful complication and death.

Axios: FDA Weighs KarXT, First Schizophrenia Drug Shift In Decades

The Food and Drug Administration is slated to decide Thursday whether to approve the first new schizophrenia drug in at least three decades. The complex condition is currently treated with antipsychotics that carry safety risks like metabolic disorders, cause weight gain and often cause people to stop taking their medications. (Goldman, 9/26)

Reuters: Pfizer Withdraws Sickle Cell Disease Treatment On Risk Of Complication, Death

U.S. drugmaker Pfizer said on Wednesday it is withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths. Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. (9/25)

Reuters: Merck's Colorectal Cancer Therapy Fails Late-Stage Trial 

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously treated patients with a type of colorectal cancer. This is the latest failure in a set of trials studying a combination involving Keytruda at a time the drugmaker seeks to expand its use in types of cancers not yet treated by immunotherapies while facing a loss of patent protection for the drug at the end of the decade. (9/25)

Stat: Study Finds MRI Cuts Overdiagnosis In Prostate Cancer Screening

Prostate cancer presents a tricky screening challenge. Catching it early could mean dodging a painful journey with advanced cancer. Yet a sizable majority of prostate cancers are “indolent” — slow growing tumors that most likely would never metastasize during the patient’s lifetime, and whose treatment  would do more harm than good. (Chen, 9/25)

Stat: Sleep Apnea On Apple Watch: Experts See Potential, Not Perfection

This month, Apple launched a feature for the Apple Watch that alerts users if it determines they may have sleep apnea, potentially leading to treatment for a dangerous health condition that often goes undiagnosed. (Aguilar, 9/26)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
  • Thursday, May 14
  • Wednesday, May 13
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF